By Rob Curran

Shares of Iqvia rallied premarket after the provider of healthcare technology and research services tightened the range for its annual earnings and revenue forecasts.

The Durham, N.C., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted earnings of $266 million, or $1.54 a share, down from $363 million, or $1.97 a share. Adjusted earnings came to $2.81 per share, topping the average Wall Street estimate of $2.77.

Revenue rose 5.3% to $4.02 billion, topping the average analyst forecast of $3.96 billion, according to FactSet. Research-and-development revenue ticked up 2.5% to $2.2 billion. The backlog at its research-and-development unit also rose 5.1% to $32.1 billion, and the company expects $8.1 billion of that to be recognized as revenue in the next 12 months.

Iqvia forecast 2025 adjusted earnings in a range between $11.75 and $12.05 a share, compared with a previous estimate between $11.70 and $12.10 a share, and in line with the Wall Street target of $11.83 a share.

Iqvia is now targeting 2025 revenue between $16.1 billion and $16.3 billion, compared with a previous estimate of $16 billion to $16.4 billion and an average analyst estimate of $16.06 billion, as tallied by FactSet.

Shares of Iqvia rallied 8.2% to $172 premarket. At Monday's close, shares were down by roughly 35% from 12 months ago.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

July 22, 2025 08:30 ET (12:30 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.